Nalaganje...
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and the US for use in patients with type 2 diabetes...
Shranjeno v:
| izdano v: | Ther Adv Endocrinol Metab |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4406879/ https://ncbi.nlm.nih.gov/pubmed/25941564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042018814560735 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|